Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …

The epidermal growth factor receptor (EGFR) plays a pivotal role in cancer therapeutics, with
small-molecule EGFR inhibitors emerging as significant agents in combating this disease …

This comprehensive review undertakes a meticulous scrutiny of the synthesis and clinical
applications pertaining to small-molecule tyrosine kinase inhibitors (TKIs) directed towards …

Purpose Previous retrospective studies reported that proton-pump inhibitors (PPIs) may
decrease the efficacy of first-generation epidermal growth factor receptor tyrosine kinase …

Introduction Resistance to second-generation epidermal growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI), afatinib, is the most significant challenge in the clinical …

Lung cancer is one of the most common malignant solid tumors and the leading cause of
cancer‑associated mortality worldwide. Endocytosis is an essential physiological activity for …

Lung large cell carcinoma is a common type of lung cancer with poor prognosis. Although
targeted drugs have achieved enormous success in treating non‐small‐cell lung carcinoma …

Overview Immunotherapy with immune checkpoint inhibitors, either as monotherapy or in
combination with chemotherapy, is now established first-line treatment for patients with …

Background Drug resistance inevitably limits the efficacy of the second-generation
epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) afatinib, and the …